Dose intensification of chemotherapy should now be abandoned as a strategy, because there is no benefit but markedly more toxicity with this approach. Medscape Medical News
Newly identified genetic variants that are associated with increased susceptibility to prostate cancer have been identified, and this might help pave the way for improvement in diagnosis and treatment. Medscape Medical News
Survival rates for patients with non-Hodgkin lymphoma have improved since the early 1990s, due partly to the use of rituximab therapy. Medscape Medical News
What do clinicians need to know in 2008? Dr. Harold Burstein brings readers up to date about trastuzumab-based regimens, selecting a chemotherapy backbone, and monitoring cardiac function. Medscape Hematology-Oncology
